Glenmark Pharmaceuticals Ltd. has reported an encouraging 32% growth in net profits for 1QFY03, backed by sales improvement of 12%. It may be noted that the company's operating margins registered a sharp growth of 330 basis points inspite of the company's entry into low margin API business. The growth has been fuelled by an all round performance with both the domestic and export segment performing well.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Diluted Earnings per share*
P/E (at current price)
Glenmark is a leader in the dermatology segment which contributes around 30% to its turnover. After the acquisition of Flucort (Lyka brand) the company also has considerable presence in the steroid segment of the dermatology market. The company has also identified the anti-diabetes market as a key growth area in future. A separate marketing force catering specifically to this market has also been set up, comprising an all-India sales force of 130 medical representatives.
Domestic Formulation Sales
Export Formulation Sales
The company has made a breakthrough in the API segment. The company has placed convertible debentures of Rs 500 m with CDC Financial Services and South Asia Regional Funds, to part finance its strategy of entering into the API business. However, the API strategy can put a pressure on the margins of the company once its contribution to topline becomes sizeable. In 1QFY03, this business contributed only Rs 12 m to the topline.
The company is also eyeing generic export opportunities for which it has formed a 100% subsidiary, Glenmark Laboratories. It has also set up a new manufacturing facility at Goa as per the US FDA standards to tap generic exports to developed nations. Glenmark is expecting to get US FDA approval for this plant during 2003. It is also expecting the plant approval from Australian and South African authorities before that. Glenmark is eyeing the branded products market in the developing countries too, for which it has got 42 product registrations across 24 countries.
The company is striving to take a lead in research activities. In a significant development, the company has recently filed patent for a new anti-asthma drug, that is currently completing pre-clinical trials. The company has also initiated dialogues with various MNCs for collaborative research projects.
At the current market price of Rs 243, the stock trades at 8x FY03 expected earnings. Given the initiatives taken by the company and its focus on niche therapeutic segments one can expect the pace of growth to continue in future. The price has remained firm because of various R&D moves and the good growth showed by the company in the home market.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407